![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IAPP |
Gene summary for IAPP |
![]() |
Gene information | Species | Human | Gene symbol | IAPP | Gene ID | 3375 |
Gene name | islet amyloid polypeptide | |
Gene Alias | DAP | |
Cytomap | 12p12.1 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | A0A024RAU1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3375 | IAPP | HCC1 | Human | Liver | HCC | 2.45e-14 | 2.10e+00 | 0.5336 |
3375 | IAPP | HCC2 | Human | Liver | HCC | 7.99e-16 | 1.01e+00 | 0.5341 |
3375 | IAPP | HCC5 | Human | Liver | HCC | 3.42e-23 | 1.29e+00 | 0.4932 |
3375 | IAPP | HTA12-29-1 | Human | Pancreas | PDAC | 1.38e-07 | 5.56e-01 | 0.3722 |
3375 | IAPP | 4347-EC | Human | Pancreas | PanIN | 4.86e-05 | 4.67e-01 | 0.0572 |
3375 | IAPP | 4741-EC1 | Human | Pancreas | PanIN | 4.85e-16 | 1.03e+00 | 0.0223 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004325422 | Liver | HCC | regulation of protein-containing complex assembly | 264/7958 | 428/18723 | 5.47e-16 | 4.39e-14 | 264 |
GO:190290322 | Liver | HCC | regulation of supramolecular fiber organization | 224/7958 | 383/18723 | 1.54e-10 | 5.33e-09 | 224 |
GO:001063912 | Liver | HCC | negative regulation of organelle organization | 204/7958 | 348/18723 | 7.67e-10 | 2.37e-08 | 204 |
GO:001082112 | Liver | HCC | regulation of mitochondrion organization | 96/7958 | 144/18723 | 3.82e-09 | 1.02e-07 | 96 |
GO:003133312 | Liver | HCC | negative regulation of protein-containing complex assembly | 91/7958 | 141/18723 | 1.01e-07 | 1.98e-06 | 91 |
GO:001082312 | Liver | HCC | negative regulation of mitochondrion organization | 36/7958 | 49/18723 | 1.08e-05 | 1.24e-04 | 36 |
GO:199000011 | Liver | HCC | amyloid fibril formation | 24/7958 | 34/18723 | 8.62e-04 | 5.13e-03 | 24 |
GO:190290412 | Liver | HCC | negative regulation of supramolecular fiber organization | 90/7958 | 167/18723 | 1.90e-03 | 9.69e-03 | 90 |
GO:19059071 | Liver | HCC | negative regulation of amyloid fibril formation | 11/7958 | 13/18723 | 2.38e-03 | 1.16e-02 | 11 |
GO:19059061 | Liver | HCC | regulation of amyloid fibril formation | 12/7958 | 16/18723 | 8.74e-03 | 3.40e-02 | 12 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IAPP | SNV | Missense_Mutation | novel | c.51N>T | p.Leu17Phe | p.L17F | P10997 | protein_coding | tolerated(0.06) | benign(0.018) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IAPP | SNV | Missense_Mutation | rs200996235 | c.98N>A | p.Arg33Gln | p.R33Q | P10997 | protein_coding | deleterious(0.03) | probably_damaging(0.934) | TCGA-EK-A3GM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
IAPP | SNV | Missense_Mutation | c.124A>G | p.Thr42Ala | p.T42A | P10997 | protein_coding | deleterious(0.01) | possibly_damaging(0.492) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
IAPP | SNV | Missense_Mutation | rs200996235 | c.98N>A | p.Arg33Gln | p.R33Q | P10997 | protein_coding | deleterious(0.03) | probably_damaging(0.934) | TCGA-AG-A01N-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | SD |
IAPP | SNV | Missense_Mutation | c.28C>A | p.Leu10Ile | p.L10I | P10997 | protein_coding | tolerated(0.09) | benign(0.192) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
IAPP | SNV | Missense_Mutation | c.191N>G | p.Asn64Ser | p.N64S | P10997 | protein_coding | deleterious(0.04) | benign(0.111) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
IAPP | SNV | Missense_Mutation | novel | c.139N>G | p.Asn47Asp | p.N47D | P10997 | protein_coding | tolerated(0.9) | benign(0.028) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
IAPP | SNV | Missense_Mutation | rs763676184 | c.130N>T | p.Arg44Cys | p.R44C | P10997 | protein_coding | deleterious(0.02) | benign(0.062) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IAPP | SNV | Missense_Mutation | c.178N>A | p.Leu60Ile | p.L60I | P10997 | protein_coding | tolerated(0.14) | benign(0.197) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
IAPP | SNV | Missense_Mutation | rs369714240 | c.151N>A | p.His51Asn | p.H51N | P10997 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3375 | IAPP | DRUGGABLE GENOME, HORMONE ACTIVITY | CURCUMIN | CURCUMIN |
Page: 1 |